LogicBio Therapeutics (OTCMKTS:LOGC) Reaches New 52-Week High – Here’s What Happened

Posted by James Quigley on Oct 27th, 2026

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $15.45 and last traded at $15.3948, with a volume of 24,675 shares traded. The stock had previously closed at $15.29.

LogicBio Therapeutics Trading Up 0.9%

The company’s 50 day moving average price is $14.03 and its 200 day moving average price is $9.96. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.87 and a quick ratio of 1.24. The firm has a market cap of $705.61 million, a PE ratio of -21.14 and a beta of 2.04.

LogicBio Therapeutics (OTCMKTS:LOGC – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10). The company had revenue of $33.60 million for the quarter, compared to analysts’ expectations of $33.60 million.

LogicBio Therapeutics Company Profile

(Get Free Report)

LogicBio Therapeutics, Inc was a clinical-stage genetic medicine company focused on developing therapies for patients with serious genetic and metabolic diseases. The company’s research centered on genetic medicine technologies designed to address the underlying causes of disease rather than treat symptoms alone.

LogicBio’s principal platform, GeneRide, was developed to enable the targeted insertion of therapeutic genes into the genome. The company also pursued GeneWare, a platform intended to support gene-editing applications.